A Prospective, Phase-II Study to Evaluate the Efficacy and Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Patients With Richter's Syndrome. GIVeRS Protocol: On Behalf of the Israeli CLL Study Group
Latest Information Update: 17 Jan 2024
At a glance
- Drugs Ibrutinib (Primary) ; Obinutuzumab (Primary) ; Venetoclax (Primary)
- Indications Richter's syndrome
- Focus Adverse reactions; Therapeutic Use
- Acronyms GIVeRS Protocol
- 12 Dec 2023 Results (N=10, as of July 20, 2023) presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 22 Aug 2021 Status changed from not yet recruiting to recruiting.
- 30 Jun 2021 New trial record